Experience the company’s new data mining engine, Synapse Analytics in booth #1929
Lexington, Mass., November 21, 2022 – FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, will showcase its industry award-winning Synapse ® Enterprise Imaging portfolio, and unveil its latest solution, Synapse Analytics in booth #1929 at the 2022 Radiological Society of North America (RSNA) annual meeting held November 27 – December 1 at McCormick Place in Chicago. Synapse Analytics is the company’s new cloud-based data mining extraction engine that enables healthcare organizations to analyze business data to see current and predictive views of their business operations. The secure and customizable software engine provides tracking and insights of trends in procedure volume, patient population analysis, lab operation efficiency, profitability, and diagnostic accuracy.
Synapse Analytics can now be applied throughout Fujifilm’s Synapse Enterprise Imaging cloud-based portfolio, bringing analytics capabilities to healthcare providers and administrators across the enterprise.
“We’ve invested in our Synapse Enterprise Imaging solutions to unite all patient imaging and data from across the enterprise and make the complete patient picture available in a single viewer,” says Bill Lacy, senior vice president of medical informatics at FUJIFILM Healthcare Americas Corporation. “The launch of Synapse Analytics allows us to take this a step further by providing deeper insight into patient information as well as business operations to drive more strategic clinical, operational, and financial decision-making.”
Through Synapse Analytics, Fujifilm delivers a library of interactive, pre-defined templated and customizable reports that track:
RSNA attendees can also get hands-on with the following Synapse Enterprise Imaging solutions in booth #1929:
To learn more about Fujifilm’s innovations at RSNA 2022, visit rsna.fujimed.com
FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image-processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutions-us.fujifilm.com
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion $USD at an exchange rate of 122 yen/dollar). For more information, please visit: www.fujifilmholdings.com.